Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology
- 805 Downloads
The incidence of invasive fungal disease (IFD) is rising, but its treatment in paediatric haematology and oncology patients is not yet standardised. This review aimed to critically appraise and analyse the clinical practice guidelines (CPGs) that are available for paediatric IFD.
Electronic searches of MEDLINE, MEDLINE in-Process & Other non-Indexed Citations, the Guidelines International Network (GIN), guideline.gov and Google were performed and combined fungal disease (Fung* OR antifung*OR Candida* OR Aspergill*) with prophylaxis or treatment (prophyl* OR therap* OR treatment). All guidelines were assessed using the AGREE II tool and recommendations relating to prophylaxis, empirical treatment and specific therapy were extracted.
Nineteen guidelines met the inclusion criteria. The AGREE II scores for the rigour of development domain ranged from 11 to 92 % with a median of 53 % (interquartile range 32–69 %). Fluconazole was recommended as antifungal prophylaxis in all nine of the included guidelines which recommended a specific drug. Liposomal amphotericin B was recommended in all five guidelines giving empirical therapy recommendations. Specific therapy recommendations were given for oral or genital candidiasis, invasive candida infection, invasive aspergillosis and other mould infections.
In many areas, recommendations were clear about appropriate practice but further clarity was required, particularly relating to the decision to discontinue empirical antifungal treatment, the relative benefits of empiric and pre-emptive strategies and risk stratification.
Future CPGs could consider working to published guideline production methodologies and sharing summaries of evidence appraisal to reduce duplication of effort, improving the quality and efficiency of CPGs in this area.
KeywordsFungal infection Paediatric Guideline Critical review
Infectious Diseases Working Party
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Clinical practice guidelines
German Society of Hematology and Oncology
Fourth European Conference on Infections in Leukaemia
European Confederation of Medical Mycology
European Organisation for Research and Treatment of Cancer Mycoses Study Group
European Society of Clinical Microbiology and Infectious Diseases
Guidelines International Network
Gruppo Italiano Trapianto Midollo Osseo
Haematopoietic stem cell transplant
Infectious Diseases Society of America
Invasive fungal disease
Institute of Medicine
Spanish Society of Infectious Diseases and Clinical Microbiology
Scottish Intercollegiate Guidelines Network
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Hope WW, Castagnola E, Groll AH, et al. (2012) ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18:38–52. doi: 10.1111/1469-0691.12040 CrossRefPubMedGoogle Scholar
- 11.Groll AH, Castagnola E, Cesaro S, et al. (2014) Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327–e340. doi: 10.1016/S1470-2045(14)70017-8 CrossRefPubMedGoogle Scholar
- 14.Ruiz-Camps I, Aguado JM, Almirante B, et al. (2011) Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC. Clin Microbiol Infect 17:1–24. doi: 10.1111/j.1469-0691.2011.03477.x CrossRefPubMedGoogle Scholar
- 15.Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Taiwan Society of Pulmonary and Critical Care Medicine, et al (2010) Guidelines for the use of antifungal agents in patients with invasive fungal infections in Taiwan-revised 2009. J Microbiol Immunol Infect 43:258–263CrossRefGoogle Scholar
- 16.Sullivan KM, Dykewicz CA, Longworth DL, et al. (2001) Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program:392–421Google Scholar
- 17.Cornely OA, Arikan-Akdagli S, Dannaoui E, et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20 Suppl 3:5–26.Google Scholar
- 18.Girmenia C, Barosi G, Piciocchi A, et al. (2014) Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20:1080–1088CrossRefGoogle Scholar
- 19.Blyth CC, O’Brien TA, Palasanthiran P (2007) Australasian guidelines for antifungal therapy in neonates and children with proven, probable and suspected fungal infections. http://www.mycology.adelaide.edu.au/virtual/guidelines/. Accessed 11 Sep 2013
- 26.Chowdhary A, Meis JF, Guarro J, et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20 Suppl 3:47–75.Google Scholar
- 27.Arendrup MC, Boekhout T, Akova M, et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20 Suppl 3:76–98.Google Scholar
- 30.Institute of Medicine (2011) Clinical practice guidelines We can trust. The National Academies Press, Washington, DCGoogle Scholar